These include activating mutations in the epidermal growth factor receptor gene (EGFR) which, according to a 2016 systematic review and meta-analysis, are found in around one-third of patients with non-small cell lung cancer (NSCLC) globally [1]. Here, EGFR is linked to non-small cell lung carcinoma.